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a b s t r a c t
Purpose: This study aims to develop a multi-gene assay predictive of the clinical beneﬁts of chemotherapy in nonsmall cell lung cancer (NSCLC) patients, and substantiate their protein expression as potential therapeutic targets.
Patients and methods: The mRNA expression of 160 genes identiﬁed from microarray was analyzed in qRT-PCR
assays of independent 337 snap-frozen NSCLC tumors to develop a predictive signature. A clinical trial JBR.10
was included in the validation. Hazard ratio was used to select genes, and decision-trees were used to construct
the predictive model. Protein expression was quantiﬁed with AQUA in 500 FFPE NSCLC samples.
Results: A 7-gene signature was identiﬁed from training cohort (n = 83) with accurate patient stratiﬁcation (P =
0.0043) and was validated in independent patient cohorts (n = 248, P b 0.0001) in Kaplan-Meier analyses. In the
predicted beneﬁt group, there was a signiﬁcantly better disease-speciﬁc survival in patients receiving adjuvant
chemotherapy in both training (P = 0.035) and validation (P = 0.0049) sets. In the predicted non-beneﬁt
group, there was no survival beneﬁt in patients receiving chemotherapy in either set. The protein expression
of ZNF71 quantiﬁed with AQUA scores produced robust patient stratiﬁcation in separate training (P = 0.021)
and validation (P = 0.047) NSCLC cohorts. The protein expression of CD27 quantiﬁed with ELISA had a strong
correlation with its mRNA expression in NSCLC tumors (Spearman coefﬁcient = 0.494, P b 0.0088). Multiple signature genes had concordant DNA copy number variation, mRNA and protein expression in NSCLC progression.
Conclusions: This study presents a predictive multi-gene assay and prognostic protein biomarkers clinically applicable for improving NSCLC treatment, with important implications in lung cancer chemotherapy and
immunotherapy.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Lung cancer is the leading cause of cancer-related deaths in the
world, and non-small cell lung cancer (NSCLC) accounts for almost
80% of lung cancer deaths [1]. The heterogeneous nature of lung cancer
makes it a very difﬁcult disease to treat. Major histology of NSCLC includes lung adenocarcinoma and squamous cell lung carcinoma. Surgical resection is the major treatment for early stage NSCLC. However,
about 22–38% of stage I NSCLC patients will develop tumor recurrence
within ﬁve years following the surgery [2]. It is therefore important to
select early stage NSCLC patients for more aggressive treatment. While
⁎ Corresponding author at: 2816 HSS, West Virginia University Cancer Institute,
Morgantown, WV 26506-9300, United States.
E-mail address: lguo@hsc.wvu.edu (N.L. Guo).

adjuvant chemotherapy of stage II and stage III disease has resulted in
10–15% increased overall survival [3], the prognosis for early stage
NSCLC remains poor [4]. Currently, there are no clinically available molecular assays to predict the risk for tumor recurrence and the clinical
beneﬁts of chemotherapy in NSCLC patients.
Immunotherapy has rapidly gained attention of oncologists as an
effective and less toxic treatment than chemotherapy in patients with advanced lung cancers [5–8]. A recent study used paired single cell analysis
to compare normal lung tissue and blood with tumor tissue in stage I
NSCLC, and found that early-stage tumors had already begun to alter
the immune cells in their microenvironment [8]. These results suggest
that immunotherapy could potentially be used to treat early stage lung
cancer patients. However, predictive biomarkers of immunotherapy are
not well established except PD-1 or PD-L1, and it is unlikely that a single
marker is sufﬁcient.

https://doi.org/10.1016/j.ebiom.2018.05.025
2352-3964/© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

N.L. Guo et al. / EBioMedicine 32 (2018) 102–110

High-throughput technologies, such as microarray and RNA-seq,
promise the discovery of novel biomarkers from genome-scale studies.
The FDA conducted a systematic evaluation and suggested continued
usefulness of legacy microarray data and established microarray biomarkers and predictive models in the forthcoming RNA-seq era [9].
However, several disadvantages have limited the application of highthroughput techniques in routine clinical tests, including costs, reproducibility, and data analyses [10]. Compared with microarray and
RNA-seq, quantitative real-time RT-PCR (qRT-PCR) is more efﬁcient,
consistent, and able to measure gene expression over a greater dynamic
range. It requires only a small sample and can be modiﬁed to quantify
gene expression in formalin-ﬁxed and parafﬁn-embedded (FFPE) tissues [11]. The combined use of real-time qRT-PCR with high-throughput analysis can overcome the inherent biases of the high-throughput
techniques and is emerging as the optimal method of choice to translate
genome research into clinical practice [12]. The protein expression validation of the identiﬁed mRNA biomarkers could substantiate their ultimate functional involvements in disease, and may lead to the discovery
of potential proteomic biomarkers in abundant FFPE samples for
broader applications in community hospitals.
DNA microarray-based studies identiﬁed gene expression-based
NSCLC prognostic [13] and predictive biomarkers [14,15]. A qRT-PCR
based 14-gene assay by Kratz et al. [16] is prognostic of non-squamous
NSCLC outcome in FFPE tissues and is ready for wide-spread clinical applications. However, this 14-gene assay is limited to non-squamous
NSCLC and is not shown to be predictive of the clinical beneﬁts of
chemotherapy.
In this study, a combined analysis of genome-wide transcriptional
proﬁles and qRT-PCR was utilized to develop a multi-gene assay both
prognostic of NSCLC outcome and predictive of the beneﬁts of chemotherapy. Patient cohorts from multiple hospitals in the US and JBR.10
data [14] were used to validate this multi-gene assay. Protein expression of the identiﬁed biomarkers was also evaluated in patient tissue
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samples and correlated with the mRNA expression and DNA copy number variation to substantiate their functional involvement and potential
as therapeutic targets in chemotherapy and immunotherapy, in addition to companion tests.
2. Materials and Methods
2.1. Patient Samples
Clinical characteristics of patient cohorts used in qRT-PCR assays is
summarized in Table 1. All NSCLC patients were staged I, II, or IIIA at
the time of diagnosis. Tumor tissues were collected in surgical resections and were snap-frozen at −80 °C until used for RNA extraction.
Tumor cell content was above 50% for qRT-PCR assays. Those with missing AJCC staging information, missing histology, death within 30 days of
resection or from other disease conditions were excluded from further
analysis. A total of 122 NSCLC patient samples were obtained from
Case Western Reserve University (CWRU) Comprehensive Cancer Center. Total RNA of good quality was extracted from 89 tumor specimens.
Good quality RNA from 101 lung adenocarcinoma tumor specimens was
obtained from University of Michigan (UM) Comprehensive Cancer
Center, with detailed description of patients, tissue specimens and
mRNA quality check provided in [17]. A total of 65 NSCLC tumor specimens from NorthShore University HealthSystem Kellogg Cancer Center
and 49 specimens from West Virginia University Cancer Institute [Mary
Babb Randolph Cancer Center (MBRCC)] generated good quality mRNA.
The tissue collection in this study was approved by an Institutional Review Board (IRB) at each institution.
2.2. RNA Extraction, and Quality and Concentration Assessments
Total RNA was extracted from snap-frozen tumor tissues using a
RNeasy mini kit according the manufacturer's protocol (Qiagen, USA),

Table 1
Clinical information of non-small cell lung cancer patient cohorts collected for the qRT-PCR analysis.

Age

Sex

Smoking

AJCC stage

Chemotherapy

Histology

Differentiation

Tumor Grade

Mean (Std error)
b60
≥60
Missing
F
M
Missing
Current
Former
Never
Passive
Other
Missing
I
II
III
Missing
Yes
No
Missing
Adenocarcinoma
Squamous
Other
Missing
Well
Moderate
Moderate to Poorly
Poorly
Missing
1
2
3
Other
Missing

CWRU (n = 89)

MBRCC (n = 49)

UM (n = 101)

NorthShore (n = 65)

70.11 (0.94)
15 (15.15%)
84 (84.85%)

66.70 (1.25)
7 (14.29%)
39 (79.59%)
3 (6.12%)
23 (46.94%)
26 (53.06%)

67.04 (0.96)
28 (27.72%)
73 (72.28%)

69.64 (1.02)
7 (10.77%)
48 (73.85%)
10 (15.38%)
34 (52.31%)
21 (32.31%)
10 (15.38%)
Yes

60 (92.31%)

No

5 (7.69%)

52 (52.53%)
47 (47.47%)
43 (43.43%)
40 (40.40%)
8 (8.08%)
1 (1.01%)
1 (1.01%)
6 (6.06%)
46 (46.46%)
46 (46.46%)
6 (6.06%)
1 (1.01%)
29 (29.29%)
52 (52.53%)
13 (13.13%)
65 (65.66%)
27 (27.27%)
7 (7.07%)
5 (5.05%)
5 (5.05%)
44 (44.44%)
4 (4.04%)
35 (35.35%)
11 (11.11%)
5 (5.05%)
44 (44.44%)
36 (36.36%)
3 (3.03%)
11 (11.11%)

53 (52.48%)
48 (47.52%)

1 (2.04%)
3 (6.12%)

45 (91.48%)
27 (55.10%)
16 (32.65%)
6 (12.25%)

59 (58.42%)
16 (15.84%)
26 (25.74%)

46 (70.77%)
15 (23.08%)
4 (6.15%)

24 (23.76%)
77 (76.24%)

3 (6.12%)
18 (36.73%)
22 (4.90%)

28 (40.03%)
36 (55.38%)
1 (1.54%)
43 (66.15%)
11 (16.92%)
6 (9.23%)
5 (7.69%)
20 (30.77%)
4 (6.15%)
22 (33.85%)
17 (26.15%)
2 (3.08%)
20 (30.77%)
19 (29.23%)
21 (32.31%)

6 (12.25%)

5 (7.69%)

27 (55.10%)
20 (40.82%)
2 (4.08%)
27 (55.10%)
14 (28.57%)
8 (16.33%)

101 (100%)

28 (27.72%)
39 (38.61%)
34 (33.66%)
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followed by elution in 30 μL of RNase-free water and storage at −80 °C.
The quality and integrity of the RNA, the 28S to 18S ratio, and a visual
image of the 28S and 18S bands were evaluated on the 2100 Bioanalyzer
(Agilent Technologies, CA). RNA assessed as having good quality from
304 tumor samples was included for further analysis. The RNA concentration of each sample was assessed using a Nanodrop-1000 Spectrophotometer (NanoDrop Tech, Germany).

2.3. Generation of Complementary DNA (cDNA)
The reverse transcriptase polymerase chain reaction was used to
convert the high-quality single-stranded RNA samples to doublestranded cDNA, using an Applied Biosystems GeneAmp® PCR 9700
machine (Foster City, CA). For standardization across all samples, one
microgram of RNA was used to generate cDNA.

2.4. Real-time Quantitative RT-PCR Low-density Arrays
Real-time qRT-PCR assays of independent patient cohorts of NSCLC
tumor samples were used to further select biomarkers to form a
multi-gene assay from prognostic genes identiﬁed from microarray
data in our previous studies [18–21]. The identiﬁed prognostic genes
were initially validated with multiple independent NSCLC microarray
data publically available [18–21]. Based on the validation results, 160
prognostic genes and three housekeeping genes were included in the
qRT-PCR experiments. The three housekeeping genes were 18S, UBC,
and POLR2A due to their conﬁrmed constant mRNA expressions across
samples [18].
We analyzed 337 tumor samples with good RNA quality using
TaqMan microﬂuidic low-density array (LDA) plates on an ABI
7900HT Fast RT-PCR instrument (Applied Biosystems). Total RNA samples were analyzed on an Agilent 2100 Bioanalyzer RNA 6000 Nano
LabChip. The report was generated by the SDS2.3 software (Applied
Biosystems). In the report, the number of cycles required to reach
threshold ﬂuorescence (Ct) and ΔCT for each sample relative to the control gene deﬁnes the expression pattern for a gene. The gene expression
data were further analyzed using the 2−ΔΔCT method [22].

2.5. Statistical and Computational Analysis
Prognostic biomarkers were evaluated with Cox proportional hazard
model. Hazard ratio was used in the evaluation of prognostic performance of biomarkers. If a biomarker gives a hazard ratio N 1, it means
that patient samples predicted as high risk are more likely to have a
poor outcome. In the evaluation of genes in qRT-PCR assays, ΔCT was
used as a covariate in Cox model. If a gene as a hazard ratio N 1, it
means that down-regulation of this gene is associated with a poor outcome and up-regulation of this gene is associated with a good outcome
in NSCLC patients; otherwise, if a gene has a hazard ratio b 1, it means
that down-regulation of this gene is associated with a good outcome
and up-regulation of this gene is associated with a poor outcome in
NSCLC patients. During the evaluation, UBC (Hs00824723_m1) was chosen as the house keeping gene to normalize gene expression. The CWRU
cohort was used as the training set, and seven genes were selected to
form a prognostic classiﬁer based on decision trees. These seven genes
are ABCC4 (Hs00988717_m1), CCL19 (Hs00171149_m1), SLC39A8
(Hs00223357_m1), CD27 (Hs00154297_m1), FUT7 (Hs00237083_m1),
DAG1 (Hs00189308_m1), and ZNF71 (Hs00221893_m1). The 7-gene
prognostic model was validated with independent patient cohorts (UM,
MBRCC, and NorthShore). In Kaplan-Meier analysis, log-rank tests or
Wilcoxon tests were used to assess the difference in probability of survival of different prognostic groups. All the analyses were performed
with packages in R or SAS unless otherwise speciﬁed.

2.6. Validation on Clinical Trial JBR.10
Data from JBR.10 was obtained from NCBI Gene Expression Omnibus
with accession number GSE14814 (https://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=gse14814). A total of 133 non-small cell lung cancer
samples were proﬁled for gene expression using Affymetrix 133A platform [14]. Patients were all in early stage (I or II). Patient samples
assayed in the same batch with consecutive accession numbers ranging
from GSM370913 to GSM371002 (n = 90) were used in the validation
of the 7-gene signature. Among these patient samples, those who died
from other disease conditions were excluded from further analysis.
ABCC4 (203196_at), CCL19 (210072_at), CD27 (206150_at), DAG1
(205417_s_at and 212128_s_at), FUT7 (210506_at and 217696_at),
SLC39A8 (209266_s_at, 209267_s_at, 216504_s_at, and 219869_s_at),
and ZNF444 (218707_at and 50376_at) were used in validating the
qRT-PCR based multi-gene assay. For a gene with multiple probe
sets, the one with the highest expression value (yielding the clearest
signal) in each sample was chosen to represent the gene expression.
ZNF71 was not available in the GSE14814 dataset. ZNF444 was chosen to replace ZNF71 to validate the qRT-PCR results, because both
ZNF444 and ZNF71 are at locus NC_000019.10 in Chromosome 19
and belong to zinc ﬁnger protein family. To be compatible with the
ΔCt values in qRT-PCR data, log2 transformed microarray data was
used in the analysis, and the expression values of UBC minus those
of selected probes were used in the normalization of the microarray
data.
2.7. Tissue Microarrays (TMA)
Samples from 2 retrospective collections of lung cancer were examined in TMA format from Yale University Pathology Archives; Cohort A (YTMA 250 [n = 298]) and Cohort B (YTMA 79 [n = 202]).
TMAs consisted of 0.6 mm cores in 1 (Cohort A) and 2 fold (Cohort
B) redundancy. TMAs were prepared according to standard
methods. Cohort A comprises 314 serially collected NSCLC who
underwent surgical resection of their primary tumor between
2004 and 2011. Cohort B comprises of 202 serially collected NSCLC
patients who underwent surgical resection of their primary tumor
between 1988 and 2003. All tissue was used after approval from
the Yale Human Investigation Committee protocol #9505008219,
which approved the patient consent forms or in some cases waiver
of consent. The actual number of samples analyzed for each study
is lower, due to unavoidable loss of tissue or the absence or limited
tumor cells in some spots as is commonly seen in TMA studies.
NSCLC patients in stage I, II, and IIIA were included in the analysis.
Those who died with no evidence of disease were excluded from further analysis.
2.8. Quantitative Immunoﬂuorescence
FFPE whole-tissue sections, tissue microarrays (TMAs) and cell pellets were processed at Yale Cancer Center/Pathology Tissue Microarray
Facility with details provided in Supplementary File 1.
Primary antibodies were followed by incubation with Alexa 546–
conjugated goat anti-mouse secondary antibody (Life Technologies) diluted 1:100 in rabbit EnVision reagent (Dako) for 1 h. ZNF71 signal was
ampliﬁed with Cy5-Tyramide (Perkin Elmer) for 10 min, and then nuclei were stained with 0.05 mg DAPI in BSA-tween for 10 min. Slides
were mounted with ProlongGold (Life Technologies). Two TBS-T and
one TBS wash was performed between each step after the primary
antibody.
Immunoﬂuorescence was quantiﬁed using automated quantitative
analysis (AQUA) Fluorescent images of DAPI, Cy3 (Alexa 546cytokeratin), and Cy5 (ZNF71) for each TMA spot were collected.
Image analysis was carried out using the AQUAnalysis software (Navigate Biopharma Inc.), which generated an AQUA score for each
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compartment by dividing the sum of target pixel intensities by the area
of the compartment in which the target is measured. AQUA scores were
normalized to the exposure time and bit depth at which the images
were captured, allowing scores collected at different exposure times
to be directly comparable. Specimens with b5% tumor area per region
of interest were not included in AQUA analysis for not being representative of the corresponding tumor specimen.

2.9. Enzyme-Linked Immunosorbent Assay (ELISA)
A total of 38 NSCLC patient tissue samples were selected for ELISA assays, including 29 tumor resections of lung adenocarcinoma and squamous cell lung cancer and 9 matched adjacent normal lung tissue
samples. The DuoSet ELISA Development Systems from R&D Systems
(Minneapolis, MN; catalog number: DY382-05) were used for quantifying protein expression of T-Cell Activation Antigen CD27 (CD27)/Tumor
Necrosis Factor Receptor Superfamily, Member 7 (TNFRSF7) in NSCLC
patient tissue samples, according to manufacturer's protocol. The
ELISA assay results were quantiﬁed using the Synergy H1 Hybrid
Multi-Mode Microplate Readers from BioTek Instruments, Inc. (Winooski, VT). Samples that yielded a positive OD values were included for
further analysis. Statistical analysis was done using a two-sample ttest assuming unequal variances. The concordance between CD27
mRNA and protein expression was evaluated with Spearman correlation coefﬁcient.

Training Set

High-risk

105

3. Results
3.1. A 7-Gene NSCLC Prognostic and Predictive Assay
The NSCLC prognostic biomarkers identiﬁed with hybrid feature selection models [18,19] and molecular network approach [20,21] in our
previous studies were validated with multiple independent microarray
datasets. Based on the validation results in microarray data, 160 genes
were selected for assays using low-density microﬂuidic qRT-PCR arrays.
Among 160 genes analyzed in the qRT-PCR assays, a 7-gene signature
was identiﬁed from training cohort obtained from Case Western Reserve University (CWRU; n = 83). Details of the decision tree based 7gene prognostic and predictive model are provided in Supplementary
Fig. 1. In the training cohort (CWRU), the 7-gene model stratiﬁed patients into two prognostic groups with signiﬁcantly different diseasespeciﬁc survival (P = 0.0043; Fig. 1A). Moreover, in the 7-gene assay
predicted chemotherapy beneﬁt (high-risk) patient group, there was a
signiﬁcantly prolonged disease-speciﬁc survival (P = 0.035; Fig. 1B) in
adjuvant chemotherapy treated patients (ACT) compared with the observation group (OBS) who did not receive any chemotherapy. Speciﬁcally, the 30 months survival rate was b0.4 in the high-risk patients
who did not receive chemotherapy (the OBS group), and the 30 months
survival rate was 100% (5/5) in patients receiving adjuvant chemotherapy (the ACT group). In contrast, there was no survival beneﬁt in receiving chemotherapy (P = 0.31; Fig. 1C) in the 7-gene assay predicted nonbeneﬁt (low-risk) group. Consistent prognostic and predictive results

Validaon Set

High-risk

Low-risk

Low-risk

Fig. 1. Kaplan-Meier analyses of the 7-gene model. Patient stratiﬁcation in training cohort CWRU (A), CWRU high-risk group (B), CWRU low-risk group (C), validation set (D), validation
set high-risk group (E), and validation set low-risk group (F). ACT: Adjuvant chemotherapy group; OBS: observation group without chemotherapy. The validation set includes patient
cohorts from MBRCC, UM, JBR.10, and Northshore. The 7-gene signature stratiﬁed patients into high-risk and low-risk groups in both training (A) and validation (D) sets. In the highrisk groups from training (B) and validation (E) sets, there were signiﬁcant survival beneﬁts in patients receiving adjuvant chemotherapy (the ACT group) compared with those who
did not receive any chemotherapy (the OBS group). In the low-risk groups from training (C) and validation (F) sets, there were no signiﬁcant survival beneﬁts in patients receiving
adjuvant chemotherapy (the ACT group) compared with those who did not receive any chemotherapy (the OBS group). P values were assessed with log-rank tests.
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were conﬁrmed in the validation set (n = 248), including NSCLC patients from another three hospitals (UM, MBRCC, and NorthShore) as
well as a clinical trial JBR.10 [14] (Fig. 1D–F). In the validation set, the
7-gene signature generated signiﬁcant prognostic stratiﬁcation (P b
0.0001; Fig. 1D). In the predicted beneﬁt (high-risk) patient group,
there was a signiﬁcant prolonged disease-speciﬁc survival in the ACT
group compared with the OBS group (P = 0.0049; Fig. 1E). Speciﬁcally,
the 5-year survival rate was 70.9% (39/55) in the high-risk patients who
received adjuvant chemotherapy (the ACT group), whereas the 5-year
survival rate was 45.8% (22/48) in high-risk patients who did not receive adjuvant chemotherapy (the OBS group). In contrast, in the predicted non-beneﬁt (low-risk) group, there was no survival beneﬁt in
the ACT group compared with the OBS group (P = 0.46, Fig. 1F). It is
noteworthy that in the predicted non-beneﬁt (low-risk) group, patients
who received adjuvant chemotherapy (ACT) had a worse post-surgical
survival in the long term compared with those who did not receive
any chemotherapy (OBS) in both training and validation sets (Fig. 1C
and F). These results further corroborate the 7-gene model prediction
of non-beneﬁt that patients would suffer from unnecessary cytotoxicity
side-effects of chemotherapy instead of beneﬁting from it. Overall, these
results demonstrate that the 7-gene assay is both prognostic of NSCLC
clinical outcome and predictive of the beneﬁts from chemotherapy.
The chemoresponse prediction for speciﬁc therapeutic agents was
examined in the identiﬁed 7 biomarkers. In particular, gene expression
of ATP binding cassette subfamily C member 4 (ABCC4) was predictive
of chemoresistance in patients receiving carboplatin, cisplatin, and
Taxol, with under-expressed mRNA (higher ΔCt) value associated with
signiﬁcantly decreased hazard ratio of death from disease and tumor recurrence (Table 2). In patients treated with carboplatin plus Taxol, using
ΔCt value of ABCC4 in Cox model, the hazard ratio of death from disease
of was 0.43 (95% CI: [0.208, 0.888], P = 0.02) and the hazard ratio of recurrence was 0.343 (95% CI: [0.122, 0.968], P = 0.04), both statistically
signiﬁcant. In patients treated with Taxol, the hazard ratio of death from
disease of ABCC4 ΔCt value was 0.403 (95% CI: [0.194, 0.834], P = 0.01,
Cox model) and the hazard ratio of recurrence was 0.48 (95% CI: [0.253,
0.912], P = 0.02, Cox model), both statistically signiﬁcant. In patients
treated with either carboplatin plus Taxol, carboplatin plus Taxotere,
cisplatin plus Taxotere, or cisplatin plus Taxol, the hazard ratio of
death from disease of ABCC4 ΔCt values was borderline signiﬁcant (hazard ratio: 0.528 [0.271, 1.028], P = 0.06, Cox model) and the hazard
ratio of recurrence was signiﬁcant at 0.545 (95% CI: [0.298, 0.998], P =
0.049, Cox model; Table 2). The expression of fucosyltransferase 7
(FUT7) was predictive of chemosensitivity to carboplatin, with underexpressed mRNA (higher ΔCt value) associated with signiﬁcantly increased hazard ratio of death from disease (hazard ratio: 1.605 [1.058,
2.435], P = 0.026, Cox model; Table 2). The expression of zinc ﬁnger
protein 71 (ZNF71) was also predictive of chemosensitivity in patients
treated with either carboplatin plus Taxol, carboplatin plus Taxotere,

cisplatin plus Taxotere, or cisplatin plus Taxol, with a signiﬁcant hazard
ratio of death from disease 1.986 (95% CI: [1.001, 3.938], P = 0.049, Cox
model; Table 2). Solute carrier family 39 member 8 (SLC39A8) was predictive of chemoresistance to Taxol, with a borderline signiﬁcant hazard
ratio of recurrence 0.584 (95% CI: [0.33, 1.03], P = 0.06, Cox model;
Table 2). The expression of SLC39A8 was also predictive of
chemoresistance to Alimta, with a borderline signiﬁcant hazard ratio
of recurrence 0.49 (95% CI: [0.219, 1.098], P = 0.08, Cox model; Table 2).
The 7-gene NSCLC prognostic and predictive signature is involved in
cell to cell signaling and interaction, inﬂammatory response, and cellular movement in Ingenuity Pathway Analysis (Qiagen, Redwood City,
CA). Based on the molecular network of the 7 NSCLC biomarkers (Supplementary Fig. 2A), these identiﬁed biomarkers have interactions
with major inﬂammatory and cancer signaling hallmarks such as TNF,
PI3K, NF-κB, and TGF-β. The top pathways involving the 7 signature
genes and their interaction partners are nNOS signaling in skeletal muscle cells, CD27 signaling in lymphocytes, and agrin interactions at neuromuscular junction (Supplementary Fig. 2B). The 7-gene signature
identiﬁed in this study does not overlap with the NSCLC gene signatures
reported in previous studies [13,15–17,23–25].
3.2. Protein Expression of ZNF71 is Prognostic of NSCLC Outcome
To substantiate the functional involvement of the identiﬁed 7 signature genes, protein expression of these biomarkers was evaluated with
immunohistochemistry (IHC). Based on the IHC results, biomarkers
with staining of good quality in FFPE NSCLC tumor tissues were further
quantiﬁed with AQUA. Protein expression of ZNF71 was identiﬁed as
prognostic of NSCLC outcome in two TMA cohorts (Fig. 2A). Details of
the AQUA assays and results are provided in Supplementary File 1.
Based on the quantitative AQUA scores representing ZNF71 protein
expression levels in tumor tissues, a cutoff point was deﬁned for patient
prognostic stratiﬁcation in training cohort YTMA250 (n = 145).
Speciﬁcally, when loge-transformed ZNF71 AQUA scores were greater
than or equal to 7.9, patients had signiﬁcantly better disease-speciﬁc
survival (P = 0.021) than those with a lower ZNF71 protein expression
level (Fig. 2B). This cutoff was further validated with signiﬁcant
patient stratiﬁcation (P = 0.047, Fig. 2C) in an independent cohort
YTMA79 (n = 46). Higher protein expression of ZNF71 is signiﬁcantly
associated with better patient survival, which is concordant with its
mRNA results in multiple independent patient cohorts and its observed
association with chemosensitivity in Taxol (Taxotere) plus platinumbased treatment in NSCLC patients (Table 2). These results indicate
that ZNF71 is a prognostic protein biomarker and might be a potential
therapeutic target of NSCLC. Furthermore, ZNF71 had a 7% (19/271) of
loss of DNA copy number in tumors vs. normal lung tissues in a NSCLC
patient cohort from Starczynowski et al. [26] (n = 271; Supplementary
Table 1). These results suggest the concordance in the loss of DNA copy

Table 2
Predictive biomarkers of chemoresponse in non-small cell lung cancer. Hazard ratios were computed with Cox proportional hazard model using ΔCt values in qRT-PCR assays.
Genes

Chemotherapeutic agents

Hazard ratio of death from disease with 95% CI

Hazard ratio of recurrence with 95% CI

Chemosensitive/resistant

ABCC4

Carboplatin + Taxol
Taxol
Carboplatin + Taxol
Carboplatin + Taxotere
Cisplatin + Taxotere
Cisplatin + Taxol
Carboplatin
Carboplatin + Taxol
Carboplatin + Taxotere
Cisplatin + Taxotere
Cisplatin + Taxol
Taxol
Alimta

0.43 [0.208, 0.888]⁎
0.403 [0.194, 0.834]⁎
0.528 [0.271, 1.028]#

0.343 [0.122, 0.968]⁎
0.48 [0.253, 0.912]⁎
0.545 [0.298, 0.998]⁎

Chemoresistant
Chemoresistant
Chemoresistant

1.605 [1.058, 2.435]⁎
1.986 [1.001, 3.938]⁎

–

Chemosensitive
Chemosensitive

–
–

0.584 [0.33, 1.03]#
0.49 [0.219, 1.098]#

Chemoresistant
Chemoresistant

FUT7
ZNF71

SLC39A8

⁎ Hazard ratio signiﬁcant at P b 0.05.
#
Hazard ratio borderline signiﬁcant at P b 0.08.
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(a)
ZNF71 High Expression

ZNF71 Medium Expression
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ZNF71 Negave

ZNF71 Low Expression

loge(ZNF71 AQUA Score) ≥ 7.9
loge(ZNF71 AQUA Score) < 7.9

(b)

YTMA79

B
n=90
n=55

P=0.021

Survival Probability

Survival Probability

YTMA250

n=27

C

n=19

P=0.047

Time (months)

Time (months)

Fig. 2. Kaplan-Meier analyses of ZNF71 protein expression quantiﬁed by AQUA. ZNF71 immunoﬂuorescence images of different expression levels in TMA. Patients were stratiﬁed into two
groups based on ZNF71 AQUA scores. Patients with loge(ZNF71 AQUA Score) ≥ 7.9 had a low-risk and those with loge(ZNF71 AQUA Score) b 7.9 had a high-risk for tumor metastasis in
training cohort YTMA250 (B) and validation cohort YTMA79 (C). P values were assessed with Wilcoxon tests.

number, down-regulated mRNA and protein expression of ZNF71 in
lung cancer progression.

3.3. Concordant mRNA and Protein Under-expression of CD27 in NSCLC
Progression
The protein expression level of CD27 was quantiﬁed with ELISA assays in NSCLC tumor tissues (n = 29) and normal adjacent lung tissues
(n = 9). Spearman correlation coefﬁcient between mRNA and protein
expression of CD27 is 0.494 (P b 0.0088; Fig. 3A) in tumor tissues.
CD27 had an average protein expression of 599.06 pg/mL in low-risk patients with a better disease-speciﬁc survival, and an average protein expression of 245.5 pg/mL in high-risk patients with a poorer diseasespeciﬁc survival in ELISA assays. CD27 had signiﬁcant under-expression
in high-risk patients vs. low-risk patients at mRNA level with a foldchange of 0.17 (P b 0.00001) and a fold-change of 0.41 (P b 0.02) at protein level (Fig. 3B). CD27 had an average protein expression of
191 pg/mL in normal lung tissues. CD27 had signiﬁcant protein over-expression in NSCLC tumor vs. normal tissues with a fold-change of 2.56 (P
b 0.025), while mRNA expression in tumor vs. normal tissues was not
signiﬁcantly different (Fig. 3B). The over-expressed CD27 protein in
NSCLC tumors is concordant with an observed 4% (11/271) of gain or
ampliﬁcation of DNA copy number in tumors vs. normal lung tissues
in the NSCLC patient cohort from Starczynowski et al. [26] (n = 271;
Supplementary Table 1). Overall, these results demonstrate that CD27
had concordant under-expression at both mRNA and protein levels in
NSCLC patients with a poor outcome and a greater chance of tumor recurrence and metastasis. The overexpressed CD27 protein level in
NSCLC tumor vs. normal lung tissues indicates that CD27 regulation in
tumorigenesis and metastatic processes is different. Our results conﬁrm
the potential role of CD27 as a target in lung cancer immunotherapy
[27,28].

4. Discussion
Lung cancer is the second most common cancer in both men and
women, and remains the highest cancer-related mortality with a
death rate higher than colon, prostate, and breast cancer combined. Currently, there is no clinically available multi-gene assay to prognosticate
and predict the beneﬁts of chemotherapy in NSCLC patients for improved personalized treatment. Immunotherapy is more effective and
less toxic than chemotherapy in advanced lung cancers [5–8,29,30],
and recent studies show promise of immunotherapy in early stage
lung cancer patients [8]. Nevertheless, predictive biomarkers and therapeutic targets of immunotherapy are not well established.
There were abundant publically available microarray data generated
in NSCLC patient tissues. Although microarray platforms are phasing
out, the legacy data and biomarkers identiﬁed in microarray platforms
are still useful in the RNA-seq era [9]. However, high-throughput platforms such as microarrays and RNA-seq are not suitable for routine clinical tests. Validation of biomarkers identiﬁed from high-throughput
technologies with qRT-PCR emerges as the most promising experimental protocol for developing multi-gene assays for clinical applications.
NSCLC prognostic biomarkers were identiﬁed with hybrid feature
selection models [18,19,31] and molecular network approach [20,21]
in our previous studies. The hybrid feature selection models [18,19,31]
contain multiple layers of gene selection algorithms in the process of
biomarker identiﬁcation. This scheme takes advantage of different algorithms in different stages of gene shaving, in order to identify the gene
signatures with the optimal performance. The molecular network approach [20,21] constructs genome-scale co-expression networks in
good-prognosis and poor-prognosis patient groups separately, and
compares the network structures of these two patient groups to identify
disease-speciﬁc network modules. Next, genes with concurrent co-expression with multiple major lung cancer signaling hallmarks were
pinpointed from disease-speciﬁc network modules for further gene
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(a)

ELISA (pg/mL)

CD27

R = 0.494 (P < 0.0088)

mRNA (RQ)
(b)

3.5

Fold-Change

3

*

2.5

qRT-PCR

ELISA

2
1.5
1

*

0.5

*

0

Cancer vs. normal

high-risk vs. low-risk

Fig. 3. Comparison of mRNA and protein expression of CD27 in NSCLC patient samples. (A) Scatterplot with regression line for CD27 mRNA (relative quantity) in qRT-PCR and protein
expression (pg/mL) in ELISA assays of 29 NSCLC tumor resections. RQ: relative quantity, measured as 2−Δct values in qRT − PCR with UBC as the control gene. R: Spearman correlation
coefﬁcient. (B). Comparison of CD27 fold-change in NSCLC vs. normal lung tissues and high-risk vs. low-risk NSCLC tumors in qRT-PCR and ELISA assays. High-risk NSCLC patients had
a poor survival outcome and low-risk NSCLC patients had a good survival outcome. Bar plot shows mean + SE. *: P b 0.05.

signature identiﬁcation. This approach embedded biological relevance
into biomarker identiﬁcation. The signature genes identiﬁed with
these sophisticated approaches were validated with multiple independent publically available microarray datasets. Genes with consistent expression patterns in multiple validation sets were included in qRT-PCR
assays. The 7-gene signature identiﬁed in qRT-PCR assays were prognostic and predictive of chemoresponse in patient cohorts from multiple hospitals and JBR.10.
The identiﬁed 7 signature genes have interactions with major inﬂammatory and cancer signaling hallmarks including TNF, PI3K, NF-κB,
and TGF-β (Supplementary Fig. 2A). Multiple signature genes are potential targets in cancer immunotherapy. Speciﬁcally, reduction of DAG1
may increase susceptibility of muscle ﬁbers to necrosis [32]. A study
shows that DAG-1 cells are resistant to TNF-α and IFNγ-induced apoptosis, with implications in bladder cancer progression and resistance to
immunotherapy [33]. CD27 is part of TNF receptor family, and overexpression of CD27 induces NF-κB activation involving signaling transduction of TNF receptor-associated factors [34]. CD27 was also reported as a
potential target of cancer immunotherapy [27,28]. The synergy between
PD-1 blockade and CD27 stimulation for CD8+ T-cell driven anti-tumor
immunity was reported recently [35], indicating the therapeutic potential of CD27 in neoadjuvant PD-1 blockade in resectable lung cancer
[36]. The zinc ﬁnger protein ZNF71 is induced by TNF-α [37] and
ZNF71 SNP was found to be associated with asthma in human serum
[38]. CCL19 is regulated by multiple NF-κB and INF family transcription

factors in human monocyte-derived dendritic cells [39]. ABCC4 is associated with multiple drug resistance in cancer [40] and smooth muscle
cell proliferation [41], and interacts with PI3K in cancer prognosis and
drug resistance [42]. Our results on ABCC4 in Table 2 are consistent
with its functional role and reported drug resistance. FUT7 interacts
with TNF-α in human bronchial mucosa [43] and its induction at sites
of tumor cell arrest is involved in metastasis [44]. NF-κB was reported
to regulate expression of the zinc transporter SLC39A8 [45]. Indirect interactions between TGF-β and SLC39A8 are involved in tumorigenesis
[46] and ﬁbrogenic response [47].
The 7-gene signature identiﬁed in this study does not overlap with
the NSCLC gene signatures reported in recent studies [15,16,23–25].
However, several biomarker genes identiﬁed in this study belong to
the same families or functional categories as the biomarkers identiﬁed
in [14–16]. In particular, FUT7 from the current study and FUT3 from
Kratz et al. [16] are both fucosyltransferase and involved in metabolism.
In the 12-gene prognostic and predictive signature from Tang et al. [15],
two genes belong to the same family or share similar functions as the 7gene signature. Speciﬁcally, SLC35A5 from Tang et al. [15] and SLC39A8
from this study both belong to solute carrier superfamily, and ATPase
Phospholipid Transporting 8A1 (ATP8A1) from Tang et al. [15] and ATP
Binding Cassette Subfamily C Member 4 (ABCC4) from this study are
both involved in energy metabolism. The 15-gene prognostic and predictive gene signature of JBR.10 [14] also contains two genes that
share similar functions as the 7-gene signature. ATPase Na+/K+
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Transporting Subunit Beta 1 (ATP1B1) from Zhu et al. [14] and ABCC4
from this study are again involved in energy metabolism, and ZNF236
from Zhu et al. [14] and ZNF71 identiﬁed in this study both belong to
zinc ﬁnger protein family. Overall, the 7-gene signature presented in
this study and two previous gene signatures from Zhu et al. [14] and
Tang et al. [15] are all prognostic of NSCLC outcome and predictive of
the beneﬁts of chemotherapy. These three gene signatures all contain
a biomarker related to ATP activities and energy metabolism. Other
shared gene families between the 7-gene signature and these two signatures include zinc ﬁnger protein and solute carrier superfamily. The
7-gene signature and the practical prognostic gene assay for non-squamous NSCLC by Kratz et al. [16] both contain biomarkers from
fucosyltransferase family. These common gene families shared by the
NSCLC gene signatures with promise for clinical utility might be functionally involved in tumor metastasis with implications in lung cancer
therapy.
The protein expression of the identiﬁed 7 signature genes was also
validated in this study. In particular, ZNF71 protein expression quantiﬁed with AQUA was a prognostic biomarker in two NSCLC patient cohorts (n = 191). Higher mRNA and protein expression of ZNF71 is
both associated with good prognosis, and ZNF71 mRNA is predictive of
chemosensitivity in Taxol (Taxotere) plus platinum-based treatment
in NSCLC patients. These results demonstrate that ZNF71 mRNA and
protein expression can both be used in prognostication of NSCLC in clinical applications and ZNF71 may be a therapeutic target. CD27 had
highly correlated mRNA and protein expression, with signiﬁcant
under-expression in poor prognostic (high-risk) NSCLC patients. CD27
mRNA and protein expression could potentially be used as a biomarker
and target in lung cancer immunotherapy. Protein expression of CCL19
was also conﬁrmed with ELISA in NSCLC tumor and adjacent normal tissues. CCL19 protein was under-expressed in NSCLC tumor tissues compared with normal lung tissues, with no statistically signiﬁcant
difference (results not shown). CCL19 also had lower protein expression
in poor-prognosis (high-risk) NSCLC patients compared with goodprognosis (low-risk) patients, with no statistically signiﬁcant difference
(results not shown). The trend of CCL19 protein expression was qualitatively concordant with its mRNA expression that higher expression of
CCL19 is associated with good prognostic outcome of NSCLC. CCL19
had a 12.5% (34/271) of a loss of DNA copy number in tumors vs. normal
lung tissues in the NSCLC patient cohort from Starczynowski et al. [26]
(n = 271; Supplementary Table 1), which suggests a loss of DNA copy
number and down-regulated mRNA and protein expression of CCL19
in NSCLC progression. In our previous integrated DNA copy number
and gene expression regulatory network analysis of NSCLC metastasis,
CCL19 is a driver gene and CD27 expression is modulated by CCL19 in
squamous cell lung cancer patients with good prognosis [48]. Together
with the molecular network reported in the literature (Supplementary
Fig. 2A), the interaction between CCL19 and CD27 could be through
PI3K and NF-κB complexes. In addition, FUT7 and DAG1 had concordant
loss or deletion of DNA copy number (Supplementary Table 1) and
down-regulated gene expression in NSCLC progression (Table 2 and
Supplementary Fig. 1).
5. Conclusions
This study presents a 7-gene predictive assay based on qRT-PCR to
improve NSCLC treatment in clinics. This 7-gene assay provides accurate
prognostication and prediction of the clinical beneﬁts of chemotherapy
in multiple patient cohorts from the US hospitals and the clinical trial
JBR.10. The 7-gene assay is enriched in inﬂammatory response. The
protein expression of ZNF71 is prognostic of NSCLC outcome in two independent patient cohorts, which is concordant with its mRNA expression. These results demonstrate that ZNF71 is a prognostic protein
biomarker and a potential therapeutic target of NSCLC. The protein expression of CD27 was strongly correlated with its mRNA expression in
NSCLC tumor tissues, and could potentially serve as a biomarker and
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target of immunotherapy in lung cancer. Multiple signature genes had
concordant DNA copy number variation, mRNA and protein expression
in NSCLC progression. The results presented in this study are important
for precision therapy in NSCLC patients with implications in developing
new therapeutic strategies to combat this deadly disease.
Funding
This work is supported by NIH Grants R01/R56LM009500 (Guo),
P20RR16440 ARRA Supplement (Guo), and R01ES021764 (Guo). The
WV-INBRE (IPA license) is supported by NIH Grant P20GM103434.
The content is solely the responsibility of the authors and does not necessarily represent the ofﬁcial views of the NIH.
Acknowledgements
We thank David P. Carbone (MD, PhD) at Ohio State University Comprehensive Cancer Center for insightful discussion and comments.
Disclaimer
The ﬁndings and conclusions in this report are of the authors and do
not necessarily represent the views of the National Institute for Occupational Safety and Health.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2018.05.025.
References
[1] Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med
2004;350(4):379–92.
[2] Goodgame B, et al. Risk of recurrence of resected stage I non-small cell lung cancer in
elderly patients as compared with younger patients. J Thorac Oncol 2009;4(11):
1370–4.
[3] Crino L, et al. Early stage and locally advanced (non-metastatic) non-small-cell lung
cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol 2010;21(Suppl. 5):v103–15.
[4] Byron E, Pinder-Schenck M. Systemic and targeted therapies for early-stage lung
cancer. Cancer Control 2014;21(1):21–31.
[5] Aguiar Jr PN, et al. PD-L1 expression as a predictive biomarker in advanced nonsmall-cell lung cancer: updated survival data. Immunotherapy 2017;9(6):499–506.
[6] CM, S. J, et al. Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future. Immunotherapy 2017;9(6):507–20.
[7] Kaufman HL. Rational combination immunotherapy: understand the biology. Cancer
Immunol Res 2017;5(5):355–6.
[8] Lavin Y, et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell 2017;169(4) p. 750-765.e17.
[9] Su Z, et al. An investigation of biomarkers derived from legacy microarray data for
their utility in the RNA-seq era. Genome Biol 2014;15(12):523.
[10] Hood L, et al. Systems biology and new technologies enable predictive and preventative medicine. Science 2004;306(5696):640–3.
[11] Votavova H, et al. Optimized protocol for gene expression analysis in formalin-ﬁxed,
parafﬁn-embedded tissue using real-time quantitative polymerase chain reaction.
Diagn Mol Pathol 2009;18(3):176–82.
[12] Bosotti R, et al. Cross platform microarray analysis for robust identiﬁcation of differentially expressed genes. BMC Bioinforma 2007;8(Suppl. 1):S5.
[13] Shedden K, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008;14(8):822–7.
[14] Zhu CQ, et al. Prognostic and predictive gene signature for adjuvant chemotherapy
in resected non-small-cell lung cancer. J Clin Oncol 2010;28(29):4417–24.
[15] Tang H, et al. A 12-gene set predicts survival beneﬁts from adjuvant chemotherapy
in non-small cell lung cancer patients. Clin Cancer Res 2013;19(6):1577–86.
[16] Kratz JR, et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies.
Lancet 2012;379(9818):823–32.
[17] Chen G, et al. Development and validation of a quantitative real-time polymerase
chain reaction classiﬁer for lung cancer prognosis. J Thorac Oncol 2011;6(9):1481–7.
[18] Guo NL, et al. Conﬁrmation of gene expression-based prediction of survival in nonsmall cell lung cancer. Clin Cancer Res 2008;14(24):8213–20.
[19] Wan YW, et al. Hybrid models identiﬁed a 12-gene signature for lung cancer prognosis and chemoresponse prediction. PLoS One 2010;5(8).
[20] Guo NL, et al. A novel network model identiﬁed a 13-gene lung cancer prognostic
signature. Int J Comput Biol Drug Des 2011;4(1):19–39.

110

N.L. Guo et al. / EBioMedicine 32 (2018) 102–110

[21] Wan YW, Beer DG, Guo NL. Signaling pathway-based identiﬁcation of extensive
prognostic gene signatures for lung adenocarcinoma. Lung Cancer 2012;76(1):
98–105.
[22] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time
quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods 2001;25(4):
402–8.
[23] Lau SK, et al. Three-gene prognostic classiﬁer for early-stage non small-cell lung cancer. J Clin Oncol 2007;25(35):5562–9.
[24] Navab R, et al. Prognostic gene-expression signature of carcinoma-associated ﬁbroblasts in non-small cell lung cancer. Proc Natl Acad Sci U S A 2011;108(17):7160–5.
[25] Chen HY, et al. A ﬁve-gene signature and clinical outcome in non-small-cell lung
cancer. N Engl J Med 2007;356(1):11–20.
[26] Starczynowski DT, et al. TRAF6 is an ampliﬁed oncogene bridging the RAS and NFkappaB pathways in human lung cancer. J Clin Invest 2011;121(10):4095–105.
[27] Buchan SL, Rogel A, Al-Shamkhani A. The immunobiology of CD27 and OX40 and
their potential as targets for cancer immunotherapy. Blood 2017. https://doi.org/
10.1182/blood-2017-07-741025 (blood-2017-07-741025).
[28] Turaj AH, et al. Antibody tumor targeting is enhanced by CD27 agonists through myeloid recruitment. Cancer Cell 11 Dec 2017;32(6):777–91 (e6).
[29] Bang A, et al. Multicenter evaluation of the tolerability of combined treatment with
PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy. Int
J Radiat Oncol Biol Phys 2017;98(2):344–51.
[30] Lazzari C, et al. Second-line therapy of squamous non-small cell lung cancer: an
evolving landscape. Expert Rev Respir Med Jun 2017;11(6):469–79. https://doi.
org/10.1080/17476348.2017.1326822 (Epub 2017 May 15).
[31] Guo L, et al. Constructing molecular classiﬁers for the accurate prognosis of lung adenocarcinoma. Clin Cancer Res 2006;12(11):3344–54.
[32] Ibraghimov-Beskrovnaya O, et al. Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 1992;355(6362):
696–702.
[33] Champelovier P, et al. Dag-1 carcinoma cell in studying the mechanisms of progression and therapeutic resistance in bladder cancer. Eur Urol 2001;39(3):343–8.
[34] Yamamoto H, Kishimoto T, Minamoto S. NF-kappaB activation in CD27 signaling: involvement of TNF receptor-associated factors in its signaling and identiﬁcation of
functional region of CD27. J Immunol 1998;161(9):4753–9.
[35] Buchan SL, et al. PD-1 blockade and CD27 stimulation activate distinct transcriptional programs that synergize for CD8(+) T-cell-driven antitumor immunity. Clin
Cancer Res 15 May 2018;24(10):2383–94. https://doi.org/10.1158/1078-0432.
CCR-17-3057 (Epub 2018 Mar 7).

[36] Forde PM, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med
16 Apr 2018. https://doi.org/10.1056/NEJMoa1716078 (Epub ahead of print).
[37] Mataki C, et al. A novel zinc ﬁnger protein mRNA in human umbilical vein endothelial cells is profoundly induced by tumor necrosis factor alpha. J Atheroscler Thromb
2000;7(2):97–103.
[38] Kim JH, et al. A genome-wide association study of total serum and mite-speciﬁc IgEs
in asthma patients. PLoS One 2013;8(8):e71958.
[39] Pietila TE, et al. Multiple NF-kappaB and IFN regulatory factor family transcription
factors regulate CCL19 gene expression in human monocyte-derived dendritic
cells. J Immunol 2007;178(1):253–61.
[40] Kochel TJ, Fulton AM. Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15PGDH) as determinants of PGE2 levels in cancer. Prostaglandins Other Lipid Mediat
2015;116-117:99–103.
[41] Sassi Y, et al. Multidrug resistance-associated protein 4 regulates cAMP-dependent
signaling pathways and controls human and rat SMC proliferation. J Clin Invest
2008;118(8):2747–57.
[42] Wen J, et al. The pharmacological and physiological role of multidrug-resistant protein 4. J Pharmacol Exp Ther 2015;354(3):358–75.
[43] Delmotte P, et al. Tumor necrosis factor alpha increases the expression of glycosyltransferases and sulfotransferases responsible for the biosynthesis of sialylated
and/or sulfated Lewis × epitopes in the human bronchial mucosa. J Biol Chem
2002;277(1):424–31.
[44] Laubli H, et al. L-selectin facilitation of metastasis involves temporal induction of
Fut7-dependent ligands at sites of tumor cell arrest. Cancer Res 2006;66(3):
1536–42.
[45] Liu MJ, et al. ZIP8 regulates host defense through zinc-mediated inhibition of NFkappaB. Cell Rep 2013;3(2):386–400.
[46] Chang X, et al. Ligand-independent regulation of transforming growth factor beta1
expression and cell cycle progression by the aryl hydrocarbon receptor. Mol Cell
Biol 2007;27(17):6127–39.
[47] Fang F, et al. Early growth response 3 (Egr-3) is induced by transforming growth factor-beta and regulates ﬁbrogenic responses. Am J Pathol 2013;183(4):1197–208.
[48] Iranmanesh SM, Guo NL. Integrated DNA copy number and gene expression regulatory network analysis of non-small cell lung cancer metastasis. Cancer Inform 2014;
13(Suppl. 5):13–23.

